Related Experiment Videos
[Antithrombin therapy in acute coronary syndromes]
A Maseri1, F Andreotti, L M Biasucci
1Istituto di Cardiologia, Università Cattolica del Sacro Cuore, Roma.
Cardiologia (Rome, Italy)
|December 1, 1994
Summary
Intracoronary thrombosis is key in acute coronary syndromes. Thrombin inhibitors, like heparin and newer direct agents, aim to prevent pathological thrombus formation, with new drugs showing promise but needing more study.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Context:
- Intracoronary thrombosis underlies acute coronary syndromes.
- Thrombin generation is critical for thrombus formation and progression.
- Current treatments like heparin have limitations in inhibiting clot-bound thrombin.
Purpose:
- To review the role of thrombin inhibition in acute coronary syndromes.
- To compare the efficacy and limitations of heparin versus newer direct thrombin inhibitors.
- To discuss the clinical indications for antithrombin therapies.
Summary:
- Heparin, a primary antithrombin, enhances antithrombin III's effect but doesn't inhibit clot-bound thrombin and requires monitoring.
- Newer direct thrombin inhibitors (hirudin, hirulog, argatroban) offer potential advantages like reduced monitoring and inhibition of clot-bound thrombin.
- Clinical studies suggest newer agents may be more effective but carry a higher risk of bleeding in acute myocardial infarction patients receiving thrombolysis.
Impact:
- Heparin remains indicated for unstable angina and myocardial infarction with rt-PA.
- Direct thrombin inhibitors show promise but require further clinical evaluation for safety and efficacy.
- Understanding thrombin's role guides the development of more effective antithrombotic strategies.